Boston Scientific Reports Q3 2026 Financial Results and Net Sales of $5.138 Billion

Boston Scientific Reports $5.138 Billion in Third-Quarter Sales for 2026

Boston Scientific Corporation generated net sales of $5.138 billion during the third quarter of 2026, marking a 1.5 percent increase on a reported, operational, and organic basis compared to the same period in the prior year, the company announced on October 28, 2026.

Headquartered in Marlborough, Massachusetts, the medical technology company reported GAAP net income attributable to common stockholders of $582 million, or $0.40 per share (EPS). This compares to $755 million, or $0.51 per share, for the third quarter of 2025. On an adjusted basis, the company achieved an EPS of $0.73 for the period, compared to $0.75 a year earlier, according to the official earnings report.

Mike Mahoney, chairman and chief executive officer of Boston Scientific, pointed to operational headwinds during the earnings announcement. “This has been a challenging year for Boston Scientific and I’m proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients,” Mahoney said.

Boston Scientific Reports Q3 2026 Financial Results and Net Sales of $5.138 Billion — Photo: finance.yahoo.com

Cardiovascular Division Leads Sales Growth

Financial results varied across the company’s two core reporting segments. The Cardiovascular division posted net sales of $3.406 billion, up from $3.343 billion in the third quarter of 2025, representing growth of 1.9 percent across reported, operational, and organic metrics. The MedSurg segment reached $1.733 billion in sales compared to $1.722 billion a year prior, delivering 0.6 percent growth on a reported basis and 0.7 percent on operational and organic bases.

Regionally, performance diverged sharply across international markets. The United States market grew by 0.5 percent on both reported and operational bases, reaching $3.309 billion.

FDA Clears Two StoneSmart Solutions Technologies

Alongside its financial disclosures, Boston Scientific highlighted several operational updates and regulatory milestones achieved during the quarter.

$BSX Q3 2026 earnings: Boston Scientific cuts its outlook again as Q3 sales stallBoston Scientific's growth stalled across both its heart and surgical divisions while production costs took a bite out of margins. Sales of the medical-device maker rose 1.5% to $5.1 billion,… pic.twitter.com/eIxEHLY9aL

— https://x.com/Finsee_main/status/2115398059454558648

In regulatory developments, the company received U.S. Food and Drug Administration 510(k) clearance for two technologies within its StoneSmart Solutions ecosystem.

The American Medical Association assigned Category I Current Procedural Terminology codes for renal denervation devices, such as the investigational TIVUS Renal Denervation System, and implantable tibial nerve stimulation devices like the eCoin ITNS System, effective in January 2028. Boston Scientific also entered into a strategic collaboration with Heartflow, Inc., trading on Nasdaq as HTFL, to integrate AI-powered CT-guided planning tools into percutaneous coronary intervention procedures.

Boston Scientific Updates 2026 Financial Guidance

Looking ahead, Boston Scientific updated its financial guidance for the remainder of 2026. The company estimates full-year net sales growth of approximately 4.25 percent on a reported basis and roughly 3.75 percent organically, with adjusted EPS projected between $3.16 and $3.18.

For the fourth quarter of 2026, the company projects net sales to decline by approximately 3.0 to 1.0 percent on both reported and organic bases. Additional details regarding the quarter are accessible through investors.bostonscientific.com.